Mitsubishi UFJ Trust & Banking
ALXN

Mitsubishi UFJ Trust & Banking’s Alexion Pharmaceuticals ALXN Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-151,775
Closed -$27.9M – 1417
2021
Q2 		$27.9M Sell
151,775
-8,928
-6% -$1.53M 0.06% 347
2021
Q1 		$24.7M Sell
160,703
-15,221
-9% -$2.35M 0.05% 370
2020
Q4 		$27.5M Sell
175,924
-15,317
-8% -$1.97M 0.06% 362
2020
Q3 		$21.9M Sell
191,241
-3,865
-2% -$417K 0.05% 372
2020
Q2 		$21.9M Buy
195,106
+12,093
+7% +$1.28M 0.05% 362
2020
Q1 		$16.4M Buy
183,013
+13,297
+8% +$1.31M 0.05% 373
2019
Q4 		$18.4M Buy
169,716
+593
+0.4% +$63.4K 0.04% 419
2019
Q3 		$16.5M Sell
169,123
-5,129
-3% -$578K 0.04% 417
2019
Q2 		$22M Sell
174,252
-7,737
-4% -$997K 0.07% 312
2019
Q1 		$24.3M Buy
181,989
+12,282
+7% +$1.53M 0.09% 269
2018
Q4 		$16.5M Sell
169,707
-1,826
-1% -$216K 0.07% 323
2018
Q3 		$23.8M Sell
171,533
-280,855
-62% -$35.2M 0.08% 282
2018
Q2 		$56.2M Buy
452,388
+1,384
+0.3% +$162K 0.1% 237
2018
Q1 		$50.3M Sell
451,004
-965
-0.2% -$115K 0.09% 257
2017
Q4 		$54.1M Buy
451,969
+4,491
+1% +$547K 0.09% 240
2017
Q3 		$62.8M Sell
447,478
-5,339
-1% -$725K 0.12% 203
2017
Q2 		$55.1M Buy
452,817
+6,524
+1% +$759K 0.11% 224
2017
Q1 		$54.1M Buy
446,293
+98
+0% +$12.6K 0.11% 229
2016
Q4 		$54.6M Sell
446,195
-10,213
-2% -$1.25M 0.11% 211
2016
Q3 		$55.9M Buy
456,408
+3,145
+0.7% +$405K 0.12% 209
2016
Q2 		$52.9M Buy
453,263
+8,686
+2% +$1.23M 0.12% 213
2016
Q1 		$61.9M Buy
444,577
+6,578
+2% +$966K 0.14% 174
2015
Q4 		$83.5M Sell
437,999
-26,918
-6% -$4.7M 0.19% 123
2015
Q3 		$72.7M Buy
464,917
+17,415
+4% +$3.18M 0.18% 130
2015
Q2 		$80.9M Buy
447,502
+51,090
+13% +$8.82M 0.19% 132
2015
Q1 		$68.7M Buy
396,412
+6,120
+2% +$1.11M 0.16% 157
2014
Q4 		$72.2M Buy
390,292
+25,303
+7% +$4.69M 0.17% 147
2014
Q3 		$60.5M Sell
364,989
-13,858
-4% -$2.28M 0.15% 162
2014
Q2 		$59.2M Buy
378,847
+2,213
+0.6% +$349K 0.14% 185
2014
Q1 		$57.3M Buy
376,634
+8,878
+2% +$1.41M 0.14% 187
2013
Q4 		$48.9M Sell
367,756
-4,802
-1% -$576K 0.12% 194
2013
Q3 		$43.3M Sell
372,558
-34,640
-9% -$3.8M 0.12% 209
2013
Q2 		$37.6M Buy
+407,198
New +$39.2M 0.11% 231

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's ALXN Position: Q3 2021 in Review

Mitsubishi UFJ Trust & Banking sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 151,775 shares — an estimated $27.9M sold.

Mitsubishi UFJ Trust & Banking first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $83.5M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Mitsubishi UFJ Trust & Banking reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Mitsubishi UFJ Trust & Banking sold 151,775 Alexion Pharmaceuticals shares in Q3 2021, an estimated $27.9M.
  • Mitsubishi UFJ Trust & Banking first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Mitsubishi UFJ Trust & Banking's Alexion Pharmaceuticals position peaked at $83.5M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q3 2021, filed 12 Nov 2021.